IPP Bureau
DefiniGen promotes Dr Chris Kirton to CEO
By IPP Bureau - January 21, 2022
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
By IPP Bureau - January 21, 2022
Biocon has reported consolidated financial results for the period ended December 31, 2021
Palleon announces IND clearance for first-in-class cancer immunotherapy
By IPP Bureau - January 21, 2022
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
US FDA approves Idorsia’s insomnia drug
By IPP Bureau - January 21, 2022
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
IHL Care Launches digital health centre
By IPP Bureau - January 21, 2022
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
SEC recommends regular market approval for Covishield and Covaxin
By IPP Bureau - January 20, 2022
However, these won’t be available at the nearest chemist store soon
Dolomite Bio announce launch of cost-effective Bioinformatics service
By IPP Bureau - January 20, 2022
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
Australia grants provisional registration for Novavax Covid-19 vaccine
By IPP Bureau - January 20, 2022
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Zydus receives final approval from USFDA for Vigabatrin tablets
By IPP Bureau - January 20, 2022
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets
By IPP Bureau - January 20, 2022
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
By IPP Bureau - January 20, 2022
First launches expected in H1 2022
AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
By IPP Bureau - January 20, 2022
Ram’s appointment follows the launch of the CDI India division in October 2021.
Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
By IPP Bureau - January 20, 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Natco Pharma signs agreement with Medicines Patent Pool
By IPP Bureau - January 20, 2022
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool
By IPP Bureau - January 20, 2022
They will commercialize molnupiravir in the international markets
